文献速递乳房整形与再造显微修复重建

止血障碍患者的显微外科乳房再造:围手术期风险与管理

Microsurgical Breast Reconstruction in Patients with Disorders of Hemostasis: Perioperative Risks and Management.
PubMed 文献 · Plast Reconstr Surg · 2022-09-28

该研究结合文献综述与单中心回顾性病历分析,纳入2015至2020年在资深作者中心接受显微外科乳房再造的止血障碍患者,并与血液科医生合作制定标准化风险评估与管理策略。文献共识别10项研究、29例明确止血障碍并接受显微外科乳房再造的患者;本中心11例患者完成17例显微外科乳房再造。

要点

  • 高因子VIII水平、杂合型因子V Leiden突变及杂合型凝血酶原G20210A突变是最常见的遗传性或混合性易栓条件。
  • 出血性疾病中以血小板减少、血小板功能障碍及血管性血友病或低血管性血友病因子水平最常与围手术期出血增加相关。
  • 患者在接受显微外科乳房再造前应筛查血栓或出血风险升高,筛查阳性应启动完整血液学评估,并与血液科医生进行跨学科管理。

核心结论

  • 患者在接受显微外科乳房再造前应筛查血栓或出血风险升高,筛查阳性应启动完整血液学评估;与血液科医生的跨学科管理对降低风险和获得最佳再造效果至关重要。

研究设计与样本

  • 研究为文献综述结合回顾性病历分析,纳入2015至2020年在资深作者(J.F.)中心接受显微外科乳房再造的止血障碍患者,并与血液科医生合作制定标准化风险评估与管理策略。
  • 文献综述共识别10项研究,包含29例明确止血障碍并接受显微外科乳房再造的患者;本中心11例患者共完成17例显微外科乳房再造。

主要发现

  • 高因子VIII水平、杂合型因子V Leiden突变及杂合型凝血酶原突变G20210A是最常见的遗传性或混合遗传/获得性易栓条件。
  • 遗传性抗凝血酶、蛋白C或蛋白S缺乏罕见。
  • 出血性疾病中,血小板减少、血小板功能障碍及血管性血友病或低血管性血友病因子水平最常与围手术期出血增加相关。

临床怎么用

  • 患者在接受显微外科乳房再造前应筛查血栓或出血风险升高,筛查阳性应启动完整血液学评估。
  • 与血液科医生对这些疾病进行跨学科管理对降低风险和获得最佳再造效果至关重要。

局限性

  • 证据等级为风险,IV级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical and technological advances have resulted in the widespread adoption of microsurgical breast reconstruction. Many comorbidities that potentially might impair vasculature and wound healing are no longer considered contraindications for these procedures. However, some uncertainty still prevails regarding the perioperative management of patients with disorders of hemostasis. METHODS: The authors combined a literature review with a retrospective chart review of patients with disorders of hemostasis who had undergone microsurgical breast reconstruction at the senior author's (J.F.) center between 2015 to 2020. Several disorders associated with thrombotic and/or hemorrhagic complications were identified, and a standardized risk assessment and management strategy was developed in cooperation with a hematologist. RESULTS: Overall, 10 studies were identified comprising 29 patients who had a defined disorder of hemostasis and underwent microsurgical breast reconstruction. Seventeen microsurgical breast reconstructions were performed on 11 patients at the senior author's (J.F.) center. High factor VIII levels, heterozygous factor V Leiden, and heterozygous prothrombin mutation G20210A were the most common genetic or mixed genetic/acquired thrombophilic conditions. As expected, hereditary antithrombin, protein C, or protein S deficiencies were rare. Among hemorrhagic disorders, thrombocytopenia, platelet dysfunction, and von Willebrand disease or low von Willebrand factor levels were those factors most frequently associated with increased perioperative bleeding. CONCLUSIONS: Patients should be screened for elevated risk of thrombosis or bleeding before undergoing microsurgical breast reconstruction, and positive screening should prompt a complete hematologic evaluation. Interdisciplinary management of these disorders with a hematologist is essential to minimize risks and to obtain optimal reconstructive results. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, IV.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Speck NE, Hellstern P, Farhadi J, et al. Microsurgical Breast Reconstruction in Patients with Disorders of Hemostasis: Perioperative Risks and Management. Plast Reconstr Surg. 2022. PMID: 35943960. doi:10.1097/PRS.0000000000009499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。